Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells?
Open Access
- 16 May 1994
- journal article
- Published by Wiley in FEBS Letters
- Vol. 344 (2-3), 221-224
- https://doi.org/10.1016/0014-5793(94)00378-5
Abstract
Tamoxifen decreased the efflux of the fluorescent marker drug, chloroquine, from phosphatidylcholine liposomes. Tamoxifen is a known structural‐mimic of cholesterol, which were both found to be similarly effective in preventing drug release from liposomes. This ability of tamoxifen and cholesterol to decrease drug efflux in a concentration‐dependent manner is likely to arise from their known ability to decrease membrane fluidity both in liposomes and also in cancer cells. The possible importance of the ability of tamoxifen to inhibit drug efflux from liposomes in relation to its ability to reverse multidrug resistance in cancer patients caused by the efflux of cytotoxic therapeutic agents, is discussed.Keywords
This publication has 22 references indexed in Scilit:
- High-Dose (480 mg/day) Tamoxifen with Etoposide: A Study of a Potential Multi-Drug Resistance ModulatorOncology, 1994
- Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolitesEuropean Journal Of Cancer, 1993
- How safe is tamoxifen?BMJ, 1993
- Tamoxifen and related compounds decrease membrane fluidity in liposomesFEBS Letters, 1993
- Clinical and Radiographic Response in a Minority of Patients with Recurrent Malignant Gliomas Treated with High-Dose TamoxifenNeurosurgery, 1993
- The case for clinical trials of tamoxifen for prevention of breast cancerThe Lancet, 1992
- Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinomaDigestive Diseases and Sciences, 1992
- The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anti-cancer agentBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1992
- Overview From the International Conference on Long-Term Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1992
- Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer Reported at the Tenth Year of Follow-UpActa Oncologica, 1992